£2.75m raised

University spin-out Invizius gets funding for dialysis treatment

Patient capital: Dr Eliza Makou, Dr Andy Herbert, Richard Boyd, Dr Magnus Nicolson

Invizius, a University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75 million from a consortium of investors.

The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank.

It will support the company as it conducts pre-clinical testing and manufacturing, and prepares to enter clinical trials and to raise Series A funding within 18 months.

Invizius’s technology stems from research by the company’s co-founder and CTO, Dr Andy Herbert, and his team.

Richard Boyd, co-founder and CEO of Invizius, said: “Our goal is to bring much-needed improvement to the lives of three million dialysis patients. This investment allows us to take a big step towards this, and we are delighted to have won the backing of a consortium of smart, well-funded investors.”

Invizius was Mercia’s first investment following its partnership with the University of Edinburgh. Since its initial £500,000 investment in April last year, it has worked with the company to develop its offering and attract other investors.

The Mercia team was led by Dr Nicola Broughton, head of universities, and Marcus Henderson, investment director. Ms Broughton said:“Invizius is a great example of how Mercia can ‘seed’ a university spin-out and build it to attract the attention of high-quality investors.

Leave a Reply

Your email address will not be published. Required fields are marked as *

This site uses Akismet to reduce spam. Learn how your comment data is processed.